Wave Life Sciences (WVE) news
Recent news
Wave Life Sciences Ltd: BofA Global Research cuts price objective to $17 from $19
AInvest Wire · Aug 3, 2026Wave Life Sciences Ltd: B. Riley cuts target price to $22 from $31
B.Riley Securities has revised its price target for Wave Life Sciences Ltd. (NASDAQ: WVE), lowering it to $22 from $31, while maintaining a Buy rating for the stock. This adjustment follows mixed results from the company’s Phase 1 INLIGHT trial evaluating WVE-007, an investigational therapy for…
AInvest Wire · Jul 31, 2026Wave Life Sciences: Singapore court hearing to be held July 14
Wave Life Sciences Ltd. (Nasdaq: WVE) has scheduled a hearing before the Singapore High Court on July 14, 2026, at 10:00 am (Singapore Time), regarding its proposed redomiciliation from Singapore to the United States. The company is seeking shareholder and court approvals for the Scheme of…
AInvest Wire · Jul 7, 2026Haydale - agreement expected to contribute to SMCC growth during FY26 and beyond
Haydale (AIM: HAYD), the advanced materials and clean-technology group, has announced the expansion of its partnership with Wave Utilities through a multi-year framework agreement and exclusivity arrangement. This development is expected to significantly contribute to the growth of its…
AInvest Wire · Jun 11, 2026ImportantWVE shares rise 49% pre-market on positive interim Phase 1 data showing obesity drug WVE-007 delivers GLP-1-like fat loss without muscle loss, deemed safe and well tolerated.
AInvest Wire · Dec 8, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.